Relay Therapeutics to Present at Two Key Investor Conferences in…

Event summary

Relay Therapeutics to participate in Wells Fargo Healthcare Conference on September 8, 2026, at 1:30 p.m. ET.
Company to present at Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 9:15 a.m. ET.
Fireside chats will be webcast live and available for replay for 30 days post-event.
Lead clinical asset zovegalisib in Phase 3 trial for HR+/HER2- metastatic breast cancer.
Pipeline includes programs for NRAS-driven solid tumors and Fabry disease.

The big picture

Relay Therapeutics' participation in these high-profile investor conferences comes as the company advances its lead asset, zovegalisib, through critical Phase 3 trials. The presentations will provide a platform to showcase Relay's proprietary Dynamo platform and its potential to address previously intractable targets in oncology and genetic diseases. The biotech sector is increasingly focused on precision medicine, and Relay's ability to execute on its clinical pipeline will be key to its strategic positioning against larger players and well-funded competitors.

What we're watching

Clinical Progress: The pace at which zovegalisib advances through Phase 3 trials will determine Relay's near-term valuation.
Investor Sentiment: How management's presentation at these conferences impacts investor confidence in Relay's pipeline.
Competitive Positioning: Whether Relay can differentiate its Dynamo platform in a crowded precision medicine landscape.